{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:59:25Z","timestamp":1790366365548,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00520-026-10996-1","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:19:06Z","timestamp":1785917946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer-related fatigue during treatment with neoadjuvant and\/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2648-1644","authenticated-orcid":false,"given":"Lucy","family":"Potter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-8393","authenticated-orcid":false,"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-039X","authenticated-orcid":false,"given":"Rajdeep Singh","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-2752","authenticated-orcid":false,"given":"Dori","family":"Beeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6987-705X","authenticated-orcid":false,"given":"Melissa S. Y.","family":"Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0421-054X","authenticated-orcid":false,"given":"Brandy","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-5770","authenticated-orcid":false,"given":"Yun-Jen","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9473-0335","authenticated-orcid":false,"given":"Kate","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-3991","authenticated-orcid":false,"given":"Areesha","family":"Tanveer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0464-0887","authenticated-orcid":false,"given":"Hassan Ul","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1945-4144","authenticated-orcid":false,"given":"Muaaz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-9266","authenticated-orcid":false,"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-8146","authenticated-orcid":false,"given":"Ellen","family":"Manzullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-1139","authenticated-orcid":false,"given":"Amber S.","family":"Kleckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-8594","authenticated-orcid":false,"given":"Carmen","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"10996_CR1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM (2023) Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell 41:1551\u20131566","journal-title":"Cancer Cell"},{"key":"10996_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX (2023) Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 12:10","journal-title":"Exp Hematol Oncol"},{"key":"10996_CR3","first-page":"43","volume":"25","author":"D Cella","year":"1998","unstructured":"Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:43\u201346","journal-title":"Semin Oncol"},{"key":"10996_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39046-0","volume":"13","author":"YE Kang","year":"2023","unstructured":"Kang YE, Yoon JH, Park NH, Ahn YC, Lee EJ, Son CG (2023) Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis. Sci Rep 13:12815","journal-title":"Sci Rep"},{"key":"10996_CR5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.1998.16.5.1689","volume":"16","author":"JA Broeckel","year":"1998","unstructured":"Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH (1998) Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16:1689\u20131696","journal-title":"J Clin Oncol"},{"key":"10996_CR6","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2001.19.14.3385","volume":"19","author":"D Cella","year":"2001","unstructured":"Cella D, Davis K, Breitbart W, Curt G, Fatigue C (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385\u20133391","journal-title":"J Clin Oncol"},{"key":"10996_CR7","unstructured":"(2017) National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 US Department of Health and Human Services. US Department of Health and Human Services. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed 25 Dec 2025"},{"key":"10996_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s005200100293","volume":"10","author":"GR Morrow","year":"2002","unstructured":"Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10:389\u2013398","journal-title":"Support Care Cancer"},{"key":"10996_CR9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jpainsymman.2009.09.010","volume":"39","author":"CP Escalante","year":"2010","unstructured":"Escalante CP, Kallen MA, Valdres RU, Morrow PK, Manzullo EF (2010) Outcomes of a cancer-related fatigue clinic in a comprehensive cancer center. J Pain Symptom Manage 39:691\u2013701","journal-title":"J Pain Symptom Manage"},{"key":"10996_CR10","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391","journal-title":"Ann Oncol"},{"key":"10996_CR11","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N, CheckMate I (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973\u20131985","journal-title":"N Engl J Med"},{"key":"10996_CR12","doi-asserted-by":"crossref","unstructured":"Lu S, Wu L, Zhang W, Zhang P, Wang WX, Fang WT, Xing WQ, Chen QX, Mei JD, Yang L, Tan LJ, Sun XH, Xu SD, Hu XH, Yu GH, Yu DL, Shan JL, Yang N, Chen YP, Tian H, Biosciences SJ (2023) Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study. J Clin Oncol 331(3):201\u2013211","DOI":"10.1200\/JCO.2023.41.16_suppl.8501"},{"issue":"3","key":"10996_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MC, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ (2023) Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593\u2013604","journal-title":"Nat Med"},{"issue":"3","key":"10996_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MC, Carter BW, Federico L, Reuben A, Khan MA (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504\u201314","journal-title":"Nat Med"},{"issue":"10308","key":"10996_CR15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398(10308):1344\u201357","journal-title":"Lancet"},{"issue":"10","key":"10996_CR16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M (2022) Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 23(10):1274\u201386","journal-title":"Lancet Oncol"},{"key":"10996_CR17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024)","year":"2024","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane"},{"key":"10996_CR18","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson M, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"10996_CR19","unstructured":"Potter L, Lopez-Olivo M (2025) The fatigue of adjuvant\/neoadjuvant immunotherapy: a systematic review with meta-analysis. OSF. osf.io\/5zfrk. Accessed 25 Dec 2025"},{"key":"10996_CR20","unstructured":"Covidence systematic review software, Veritas Health Innovation Melbourne, Australia. www.covidence.org. Accessed 25 Dec 2025"},{"key":"10996_CR21","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"10996_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"10996_CR23","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman AD (eds) (2013) GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. www.guidelinedevelopment.org\/handbook. Accessed 24 Dec 2025"},{"key":"10996_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116937","author":"SP Chawla","year":"2023","unstructured":"Chawla SP, Tellez WA, Chomoyan H, Valencia C, Ahari A, Omelchenko N, Makrievski S, Brigham DA, Chua-Alcala V, Quon D, Moradkhani A, Gordon EM (2023) Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311). Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1116937","journal-title":"Front Oncol"},{"key":"10996_CR25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.24.00773","volume":"43","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthelemy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grunwald V (2024) Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: part B of the randomized, placebo-controlled, phase III CheckMate 914 trial. J Clin Oncol 43:189\u2013200","journal-title":"J Clin Oncol"},{"issue":"10379","key":"10996_CR26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthelemy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albiges L, George S, Shuch B, Sosman J, Staehler M, Vazquez Estevez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401(10379):821\u2013832","journal-title":"Lancet"},{"issue":"1","key":"10996_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM (2022) A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC)-NCI 10013. NPJ breast cancer. 8(1):134","journal-title":"NPJ breast cancer."},{"issue":"8","key":"10996_CR28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, Drake CG, Signoretti S, Akgul M, Baniak N, Li-Ning E, Palmer MB, Emamekhoo H, Adra N, Kaimakliotis H, Ged Y, Pierorazio PM, Abel EJ, Bilen MA, Ogan K, Moon HH, Ramaswamy KA, Singer EA, Mayer TM, Lohrey J, Margulis V, Gills J, Delacroix SE, Waples MJ, James AC, Wang P, Choueiri T, Michaelson MD, Kapoor A, Heng DY, Shuch B, Leibovich BC, Lara PN, Manola J, Maskens D, Battle D, Uzzo R, Bratslavsky G, Haas NB, Carducci MA (2024) Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol 25(8):1038\u20131052","journal-title":"Lancet Oncol"},{"issue":"6","key":"10996_CR29","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC (2021) Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol 22(6):824\u2013835","journal-title":"Lancet Oncol"},{"key":"10996_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E et al (2018) Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24:1649\u20131654","journal-title":"Nat Med"},{"issue":"22","key":"10996_CR31","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Antonio JN, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"4","key":"10996_CR32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O\u2019Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(4):525\u2013537","journal-title":"Lancet Oncol"},{"issue":"11","key":"10996_CR33","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone T, Kar G, Spicer JD, Garcia-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM (2023) Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov 13(11):2394\u20132411","journal-title":"Cancer Discov"},{"issue":"8","key":"10996_CR34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385(8):683\u2013694","journal-title":"N Engl J Med"},{"issue":"19","key":"10996_CR35","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, Van Den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, Van Akkooi ACJ, Suciu S, Robert C (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789\u20131801","journal-title":"N Engl J Med"},{"issue":"5","key":"10996_CR36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530","journal-title":"Lancet Oncol"},{"issue":"10","key":"10996_CR37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA (2023) Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol 34(10):907\u2013919","journal-title":"Ann Oncol"},{"issue":"5","key":"10996_CR38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos EM (2022) Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 33(5):534\u201343","journal-title":"Ann Oncol"},{"issue":"3","key":"10996_CR39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","volume":"12","author":"KF Grossmann","year":"2022","unstructured":"Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI (2022) Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma. Cancer Discov 12(3):644\u201353","journal-title":"Cancer Discov"},{"key":"10996_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39196-9","author":"T Heumann","year":"2023","unstructured":"Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, Cao H, Zhang T, Gai J, Celiker B, Zhu Q, McPhaul T, Durham J, Purtell K, Klein R, Laheru D, De Jesus-Acosta A, Le DT, Narang A, Anders R, Burkhart R, Burns W, Soares K, Wolfgang C, Thompson E, Jaffee E, Wang H, He J, Zheng L (2023) A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-39196-9","journal-title":"Nat Commun"},{"issue":"18","key":"10996_CR41","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M (2023) Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 389(18):1672\u20131684","journal-title":"N Engl J Med"},{"issue":"8","key":"10996_CR42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, Ji J, Yeh TS, Chen LT, Ryu MH, Kim JG, Omori T, Rha SY, Kim TY, Ryu KW, Sakuramoto S, Nishida Y, Fukushima N, Yamada T, Bai LY, Hirashima Y, Hagihara S, Nakada T, Sasako M (2024) Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 9(8):705\u2013717","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10996_CR43","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV (2023) Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 29(11):2835\u20132843","journal-title":"Nat Med"},{"issue":"3","key":"10996_CR44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","volume":"29","author":"HS Lee","year":"2023","unstructured":"Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM (2023) A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res 29(3):548\u2013559","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10996_CR45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30(8):1279\u20131288","journal-title":"Ann Oncol"},{"issue":"9","key":"10996_CR46","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41591-024-03077-5","volume":"30","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J (2024) Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF V600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med 30(9):2540\u20138","journal-title":"Nat Med"},{"issue":"11","key":"10996_CR47","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","volume":"23","author":"GV Long","year":"2022","unstructured":"Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA (2022) Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 23(11):1378\u20131388","journal-title":"Lancet Oncol"},{"issue":"1","key":"10996_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11136-022-03226-8","volume":"32","author":"LE McLouth","year":"2023","unstructured":"McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI (2023) Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res 32(1):183\u2013196","journal-title":"Qual Life Res"},{"issue":"10257","key":"10996_CR49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090\u20131100","journal-title":"Lancet"},{"issue":"5","key":"10996_CR50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA oncology. 6(5):676\u201384","journal-title":"JAMA oncology."},{"issue":"11","key":"10996_CR51","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, de Graaf M, Gielen RC, Bakker NA, Rolfes AL, Garner H, Boeckx B, Traets JJ, Mandjes IA, de Maaker M (2024) Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nature Medicine. 30(11):3223\u201335","journal-title":"Nature Medicine."},{"key":"10996_CR52","first-page":"15","volume":"15","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suarez C, Chang CH, Roghmann F, Ozguroglu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS (2024) Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 15:15","journal-title":"N Engl J Med"},{"issue":"6","key":"10996_CR53","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernab\u00e9 R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N (2023) Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med 389(6):504\u201313","journal-title":"N Engl J Med"},{"issue":"1","key":"10996_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46999-x","volume":"15","author":"IL Ray-Coquard","year":"2024","unstructured":"Ray-Coquard IL, Savoye AM, Schiffler C, Mouret-Reynier MA, Derbel O, Kalbacher E, Leheurteur M, Martinez A, Cornila C, Martinez M, Bengrine Lefevre L (2024) Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nat Commun 15(1):5931","journal-title":"Nat Commun"},{"issue":"6","key":"10996_CR55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O\u2019Shaughnessy J (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386(6):556\u2013567","journal-title":"N Engl J Med"},{"issue":"10","key":"10996_CR56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI (2020) Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol 6(10):1563\u20131570","journal-title":"JAMA Oncol"},{"issue":"2","key":"10996_CR57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE (2024) Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 25(2):212\u201324","journal-title":"Lancet Oncol"},{"issue":"1","key":"10996_CR58","volume":"5","author":"HW Sim","year":"2023","unstructured":"Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, Rosenthal MA (2023) NUTMEG: a randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neurooncol Adv 5(1):124","journal-title":"Neurooncol Adv"},{"issue":"11","key":"10996_CR59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","volume":"35","author":"T Van Gorp","year":"2024","unstructured":"Van Gorp T, Cibula D, Lv W, Backes F, Orta\u00e7 F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L (2024) ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol 35(11):968\u201380","journal-title":"Ann Oncol"},{"issue":"19","key":"10996_CR60","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbe C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, De Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835","journal-title":"N Engl J Med"},{"issue":"7","key":"10996_CR61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M (2022) Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res 28(7):1345\u20131352","journal-title":"Clin Cancer Res"},{"key":"10996_CR62","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","volume":"42","author":"F Xia","year":"2024","unstructured":"Xia F, Wang H, Shen L, Xiang Z, Zhao Y, Wan J, Zhang H, Wang Y, Wu R, Wang J, Yang W, Zhou M, Zhou S, Chen Y, Wu X, Xuan Y, Wang R, Sun Y, Tong T, Zhang X, Wang L, Huang D, Sheng W, Yan H, Yang X, Shen Y, Zhao R, Mo M, Cai G, Cai S, Xu Y, Zhang Z (2024) Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH). J Clin Oncol 42:3308\u20133318","journal-title":"J Clin Oncol"},{"key":"10996_CR63","volume":"12","author":"W Xing","year":"2021","unstructured":"Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T, Zhang Y, Ma B, Yang Y, Shang Y, Fu X, Liang G, Yuan D, Qu J, Chai X, Zhang H, Wang Z, Lin H, Liu L, Ren X, Zhang J, Gao Q (2021) The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study. Front Immunol 12:772450","journal-title":"Front Immunol"},{"issue":"2","key":"10996_CR64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, Sun XW, Chen YB, Guan WL, Wang ZX, Qiu HB, Wang W, Chen S, Zhang DS, Ling YH, Xi SY, Cai MY, Huang CY, Yang QX, Liu ZM, Guan YX, Chen YM, Li JB, Tang XW, Peng JS, Zhou ZW, Xu RH, Wang F (2024) Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med 30(2):552\u2013559","journal-title":"Nat Med"},{"key":"10996_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101764","author":"X Zhu","year":"2023","unstructured":"Zhu X, Liu W, Cao Y, Ju X, Zhao X, Jiang L, Ye Y, Zhang H (2023) Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial. eClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101764","journal-title":"eClinicalMedicine"},{"key":"10996_CR66","unstructured":"Medical Director, Merck Sharp & Dohme LLC (2018) Efficacy and safety of pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant\/adjuvant therapy for participants with Resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03425643. Accessed 23 Nov 2025"},{"issue":"8","key":"10996_CR67","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(21)00286-2","volume":"22","author":"X Zhu","year":"2021","unstructured":"Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H (2021) RETRACTION: stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 22(8):1093\u2013102","journal-title":"The Lancet Oncology."},{"key":"10996_CR68","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","volume":"23","author":"X Zhu","year":"2022","unstructured":"Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H (2022) Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 23:e105\u2013e115","journal-title":"Lancet Oncol"},{"key":"10996_CR69","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, Investigators K- (2024) Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 404:1240\u20131252","journal-title":"Lancet"},{"key":"10996_CR70","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100474","volume":"7","author":"I Kiss","year":"2022","unstructured":"Kiss I, Kuhn M, Hrusak K, Buchler T (2022) Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 7:100474","journal-title":"ESMO Open"},{"key":"10996_CR71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2014.10.013","volume":"136","author":"XS Wang","year":"2015","unstructured":"Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136:446\u2013452","journal-title":"Gynecol Oncol"},{"key":"10996_CR72","unstructured":"PDQ Supportive and Palliative Care Editorial Board (2002) Fatigue (PDQ\u00ae): health professional version. PDQ Cancer Information Summaries. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK66049. Accessed 23 Dec 2025"},{"key":"10996_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121943","author":"E Arico","year":"2019","unstructured":"Arico E, Castiello L, Capone I, Gabriele L, Belardelli F (2019) Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11121943","journal-title":"Cancers (Basel)"},{"key":"10996_CR74","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102962","volume":"9","author":"TA Sussman","year":"2024","unstructured":"Sussman TA, Ott PA (2024) Adjuvant immunotherapy for melanoma patients: progress and opportunities. ESMO Open 9:102962","journal-title":"ESMO Open"},{"key":"10996_CR75","volume":"101","author":"R He","year":"2022","unstructured":"He R, Zhao X, Liu J, Zhou Y, Zhang X, Cheng F (2022) PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: a systematic review and meta-analysis. Medicine (Baltimore) 101:e30561","journal-title":"Medicine (Baltimore)"},{"key":"10996_CR76","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2023.7333","volume":"10","author":"A Mangla","year":"2024","unstructured":"Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carroll BT, Theuner J, Li S, Fu P, Kirkwood JM (2024) Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy in high-risk resectable melanoma: a pooled analysis. JAMA Oncol 10:612\u2013620","journal-title":"JAMA Oncol"},{"key":"10996_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08643-8","volume":"32","author":"S Yennurajalingam","year":"2024","unstructured":"Yennurajalingam S, Thomas L, Stanton PA, Lu Z, de Moraes AR, Bruera E (2024) Cancer-related fatigue among patients with advanced cancer receiving immune-checkpoint inhibitors: a prospective study. Support Care Cancer 32:459","journal-title":"Support Care Cancer"},{"key":"10996_CR78","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","volume":"13","author":"AM Berger","year":"2015","unstructured":"Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C, National comprehensive cancer n (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Canc Netw 13:1012\u20131039","journal-title":"J Natl Compr Canc Netw"},{"key":"10996_CR79","first-page":"276","volume":"36","author":"D Gentile","year":"2022","unstructured":"Gentile D, Beeler D, Wang XS, Ben-Arye E, Zick SM, Bao T, Carlson LE, Ghelman R, Master V, Tripathy D, Zhi WI (2022) Cancer-related fatigue outcome measures in integrative oncology: evidence for practice and research recommendations. Oncology (Williston Park) 36:276\u2013287","journal-title":"Oncology (Williston Park)"},{"key":"10996_CR80","first-page":"88","volume":"28","author":"F D'Silva","year":"2022","unstructured":"D\u2019Silva F, Javeth A, Singh P (2022) Cancer-related fatigue - clinical evaluation scales and interventions: a systematic review Indian. J Palliat Care 28:88\u201398","journal-title":"J Palliat Care"},{"key":"10996_CR81","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, Schmidt H, Koller M, Oerlemans S, Velikova G, Pinto M, Tomaszewski KA, Aaronson NK, Exall E, Finbow C, Fitzsimmons D, Grant L, Groenvold M, Tolley C, Wheelwright S, Bottomley A, European Organisation for R, Treatment of Cancer Quality of Life G (2023) Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer 178:128\u2013138","journal-title":"Eur J Cancer"},{"key":"10996_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-10086-8","volume":"33","author":"CP Escalante","year":"2025","unstructured":"Escalante CP, Potter L, Bassaragh A, Manzullo E (2025) Review of a high-resourced cancer-related fatigue clinic and considerations in lower-resourced environments. Support Care Cancer 33:1007","journal-title":"Support Care Cancer"},{"key":"10996_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09764-4","volume":"33","author":"DM Beeler","year":"2025","unstructured":"Beeler DM, O\u2019Higgins CM, Brady B, Walsh D, Reilly RB (2025) Objective measurement of cancer-related fatigue. Support Care Cancer 33:716","journal-title":"Support Care Cancer"},{"key":"10996_CR84","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.081","volume":"305","author":"P Arias","year":"2015","unstructured":"Arias P, Robles-Garcia V, Corral-Bergantinos Y, Madrid A, Espinosa N, Valls-Sole J, Grieve KL, Oliviero A, Cudeiro J (2015) Central fatigue induced by short-lasting finger tapping and isometric tasks: a study of silent periods evoked at spinal and supraspinal levels. Neuroscience 305:316\u2013327","journal-title":"Neuroscience"},{"key":"10996_CR85","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1002\/cam4.2490","volume":"8","author":"LR Feng","year":"2019","unstructured":"Feng LR, Regan J, Shrader JA, Liwang J, Ross A, Kumar S, Saligan LN (2019) Cognitive and motor aspects of cancer-related fatigue. Cancer Med 8:5840\u20135849","journal-title":"Cancer Med"},{"key":"10996_CR86","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2024.1427336","volume":"18","author":"C Heimhofer","year":"2024","unstructured":"Heimhofer C, Neumann A, Odermatt I, Bachinger M, Wenderoth N (2024) Finger-specific effects of age on tapping speed and motor fatigability. Front Hum Neurosci 18:1427336","journal-title":"Front Hum Neurosci"},{"key":"10996_CR87","first-page":"230","volume":"27","author":"CJ Nightingale","year":"2019","unstructured":"Nightingale CJ, Mitchell SN, Butterfield SA (2019) Validation of the timed up and go test for assessing balance variables in adults aged 65 and older. J Aging Phys Act 27:230\u2013233","journal-title":"J Aging Phys Act"},{"key":"10996_CR88","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab N, Anouti B, Abdel-Wahab R, Gonzales Z, Spillson CA, Baum GP, Bentebibel SE, Manzano JG, McQuade J, Glitza I, Amaria R, Patel S, Wong M, Tawbi H, Davies MA, Ekmekjcioglu S, Tweardy D, Sharma P, Shete S, Peterson S, Yee C, Suarez-Almazor ME, Diab A (2023) Unveiling immune-related adverse events (irAEs) and symptom burden in melanoma patients on adjuvant immune checkpoint inhibitors (ICIs). J Immunother Cancer 11(Suppl 1):A1\u2013A1731","DOI":"10.1136\/jitc-2023-SITC2023.0444"},{"key":"10996_CR89","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.24.00541","volume":"42","author":"JE Bower","year":"2024","unstructured":"Bower JE, Lacchetti C, Alici Y, Barton DL, Bruner D, Canin BE, Escalante CP, Ganz PA, Garland SN, Gupta S, Jim H, Ligibel JA, Loh KP, Peppone L, Tripathy D, Yennu S, Zick S, Mustian K (2024) Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. J Clin Oncol 42:2456\u20132487","journal-title":"J Clin Oncol"},{"key":"10996_CR90","unstructured":"National Comprehensive Cancer Network (2026) NCCN clinical practice guidelines in oncology: cancer-related fatigue (Version 2.2026). NCCN Guidelines. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1424. Accessed 24 Dec 2025"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10996-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10996-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:02:56Z","timestamp":1790362976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10996-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10996"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10996-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"829"}}